Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Preferred Shares: 2020-2024

Historic Preferred Shares for Viridian Therapeutics, Inc.\DE (VRDN) over the last 5 years, with Dec 2024 value amounting to $127.7 million.

  • Viridian Therapeutics, Inc.\DE's Preferred Shares changed negligibly% to $127.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $127.7 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $127.7 million for FY2024, which is 0.46% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Preferred Shares of $127.7 million as of FY2024, which was down 0.46% from $128.3 million recorded in FY2023.
  • Viridian Therapeutics, Inc.\DE's Preferred Shares' 5-year high stood at $180.8 million during FY2020, with a 5-year trough of $85.5 million in FY2022.
  • In the last 3 years, Viridian Therapeutics, Inc.\DE's Preferred Shares had a median value of $127.7 million in 2024 and averaged $113.8 million.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Preferred Shares slumped by 34.64% in 2021 and then spiked by 50.09% in 2023.
  • Yearly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Preferred Shares stood at $180.8 million in 2020, then tumbled by 34.64% to $118.2 million in 2021, then dropped by 27.67% to $85.5 million in 2022, then skyrocketed by 50.09% to $128.3 million in 2023, then decreased by 0.46% to $127.7 million in 2024.